Chemistry:Nicardipine
 | |
| Clinical data | |
|---|---|
| Trade names | Cardene |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a695032 |
| Routes of administration | Oral, intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | >95% |
| Elimination half-life | 8.6 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H29N3O6 |
| Molar mass | 479.533 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 136–138 °C (277–280 °F) |
| |
| |
| (verify) | |
Nicardipine (Cardene) is a medication used to treat high blood pressure and angina. It belongs to the dihydropyridine class of calcium channel blockers (CCBs). It is also used for Raynaud's phenomenon. It is available in by mouth and intravenous formulations. It has been used in percutaneous coronary intervention.[1]
Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridine calcium channel blockers (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. It is primarily a peripheral arterial vasodilator, thus unlike the nitrovasodilators (nitroglycerin and nitroprusside), cardiac preload is minimally affected. It has the longest duration among parenteral CCBs. [2][3] As its use may lead to reflex tachycardia, it is advisable to use it in conjunction with a beta-blocker.[3][2]
It was patented in 1973 and approved for medical use in 1981.[4]
Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.[5]
See also
References
- ↑ "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheterization and Cardiovascular Interventions 68 (5): 671–676. November 2006. doi:10.1002/ccd.20885. PMID 17034064.
- ↑ 2.0 2.1 "Vasodilators". Anesthesiology Core Review: Part One Basic Exam.. McGraw Hill. 2014. ISBN 978-0-07-182137-7. https://accessanesthesiology.mhmedical.com/content.aspx?bookid=974§ionid=61590560.
- ↑ 3.0 3.1 "Hypertensive urgencies & emergencies.". Current Medical Diagnosis & Treatment. McGraw Hill. 2022. ISBN 978-1-2642-6938-9. https://accessmedicine.mhmedical.com/content.aspx?bookid=3081§ionid=258962164.
- ↑ (in en) Analogue-based Drug Discovery. John Wiley & Sons. 2006. p. 464. ISBN 978-3-527-60749-5. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA464.
- ↑ "Nicardipine". Medline Plus. U.S. National Library of Medicine. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a695032.html.
 |  |
